{"id":129855,"date":"2024-01-31T08:56:14","date_gmt":"2024-01-31T07:56:14","guid":{"rendered":"https:\/\/prod1-sb.designtech.space\/angelini-ventures-invests-eight-million-euros-in-two-u-s-startups\/129855\/"},"modified":"2024-01-31T08:56:14","modified_gmt":"2024-01-31T07:56:14","slug":"angelini-ventures-invests-eight-million-euros-in-two-u-s-startups","status":"publish","type":"post","link":"https:\/\/www.startupbusiness.it\/en\/angelini-ventures-invests-eight-million-euros-in-two-u-s-startups\/129855\/","title":{"rendered":"Angelini Ventures invests eight million euros in two U.S. startups"},"content":{"rendered":"

Angelini Ventures, Angelini Industries’ international venture capital<\/a> company, founded at the end of 2022<\/strong> and already active with several investments in the health, industrial technology and consumer goods sectors such as those in Cadence Neuroscience<\/a> and Nextsense<\/a>, announces that it has completed two new transactions for a total value of approximately eight million euros.<\/strong><\/p>\n

The first of the two investments that thus open operations in 2024 concerns Noctrix Health<\/b>, a US startup that has developed the first wearable technological device to treat “restless legs syndrome”,<\/strong> a neurological disorder that causes feelings of discomfort in the lower limbs that occur mainly at night and negatively affect the quality of sleep. The second investment is aimed at COUR Pharmaceuticals,<\/b> a US-based company that uses advanced nanotechnology to treat autoimmune diseases such as type 1 diabetes and celiac disease.<\/strong><\/p>\n

Founded in 2022 with a budget of \u20ac300 million, Angelini Ventures has already planned investments of over \u20ac80 million in Europe and North America. The current portfolio includes 15 direct investments in startups (5 of which through the Angelini Lumira Biosciences Fund), the creation of two startup studios that promote technology transfer and support for a scientific research project.<\/p>\n

Wearable therapies and nanotechnology<\/h2>\n

Angelini Ventures’ investment in Noctrix Hea<\/b>lth is part of an overall $40 million Series C round led by Sectoral Asset Management, with new investors Asahi Kasei America, and Resmed, as well as Angelini Ventures itself, and strong support from other investors including OrbiMed, and Treo Ventures.<\/strong><\/p>\n

In particular, the new funding will support the development of Nidra Tonic Motor Activation<\/b> (TOMAC), the technology created by Noctrix Health, towards its long-awaited launch in the American market. Nidra Tonic Motor Activation involves the use of two bands, to be applied just below the knees, which contain a device capable of stimulating the spinal cord, through electrical impulses, and thus generating a response that activates the muscles in the lower legs and reduces the symptoms of restless leg syndrome.<\/p>\n

Nidra <\/sup>is now the first and only treatment approved by the Food and Drug Administration (FDA) to reduce symptoms and improve sleep quality in adults affected by drug-resistant forms of restless leg syndrome: in particular, Nidra obtained “De Novo” authorization for medical devices from the FDA in early 2023.<\/p>\n

On the other hand, the technology developed by COUR Pharmaceuticals<\/b>, a U.S. biotechnology company specializing in the development, with nanotechnology, of therapies aimed at reprogramming the immune system,<\/strong> is aimed at patients with autoimmune diseases, such as celiac disease and diabetes.<\/p>\n

Angelini Ventures’ investment is part of a $105 million Series A round, co-led by Lumira Ventures and Alpha Wave Ventures, with participation from Roche Venture Fund, Pfizer through the Pfizer Breakthrough Growth Initiative, Bristol Myers Squibb and JDRF T1D Fund.<\/strong><\/p>\n

The funding will allow COUR to develop phase 2 clinical trials for the treatment of autoimmune diseases, myasthenia gravis<\/b>, which causes muscle fatigue, and type 1 diabetes<\/b>. Autoimmune diseases are caused by a reaction of the immune system that mistakenly attacks healthy cells and tissues that perform important functions. The goal of COUR is to bring into the body, through nanoparticles, the very molecules that the body perceives as foreign and dangerous (antigens) to “teach” the immune system to recognize them and not attack them. The special nanotechnologies developed by COUR make it possible to convey a large quantity and variety of antigens into the body without toxic effects, thus increasing the possibility that the immune system learns not to attack them. With this type of technology, COUR has already recorded important clinical results in the field of celiac disease and cholangitis.<\/p>\n

\n","protected":false},"excerpt":{"rendered":"

These are Noctrix Health and COUR Pharmaceuticals, which develop wearable therapy devices and nanotechnology to combat diabetes and celiac disease<\/p>\n","protected":false},"author":125,"featured_media":137025,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[1317],"tags":[1460,1358,1143,1136,1145],"companies":[],"journalist":[1513],"class_list":["post-129855","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-funding-news","tag-corporate-en","tag-healthcare-en","tag-investments","tag-startup-en-2","tag-venture-capital-en-2","journalist-emil-abirascid-en"],"featured_sizes_urls":{"thumbnail":{"src":"https:\/\/www.startupbusiness.it\/wp-content\/uploads\/2024\/05\/AngeliniVentures_Team.jpg","width":150,"height":100,"crop":false,"srcset":false,"alt":""},"large":{"src":"https:\/\/www.startupbusiness.it\/wp-content\/uploads\/2024\/05\/AngeliniVentures_Team.jpg","width":1024,"height":682,"crop":false,"srcset":false,"alt":""},"2048x2048":{"src":"https:\/\/www.startupbusiness.it\/wp-content\/uploads\/2024\/05\/AngeliniVentures_Team.jpg","width":1280,"height":853,"crop":false,"srcset":false,"alt":""}},"acf":[],"yoast_head":"\nAngelini Ventures invests eight million euros in two U.S. startups<\/title>\n<meta name=\"description\" content=\"Noctrix Health and COUR Pharmaceuticals Develop Wearable Therapeutics and Nanotechnology to Fight Diabetes and Celiac Disease\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.startupbusiness.it\/en\/angelini-ventures-invests-eight-million-euros-in-two-u-s-startups\/129855\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Angelini Ventures invests eight million euros in two U.S. startups\" \/>\n<meta property=\"og:description\" content=\"Noctrix Health and COUR Pharmaceuticals Develop Wearable Therapeutics and Nanotechnology to Fight Diabetes and Celiac Disease\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.startupbusiness.it\/en\/angelini-ventures-invests-eight-million-euros-in-two-u-s-startups\/129855\/\" \/>\n<meta property=\"og:site_name\" content=\"Startupbusiness.it\" \/>\n<meta property=\"article:published_time\" content=\"2024-01-31T07:56:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.startupbusiness.it\/wp-content\/uploads\/2024\/05\/AngeliniVentures_Team.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1280\" \/>\n\t<meta property=\"og:image:height\" content=\"853\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Emil Abirascid\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@emilabirascid\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Emil Abirascid\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/angelini-ventures-invests-eight-million-euros-in-two-u-s-startups\\\/129855\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/angelini-ventures-invests-eight-million-euros-in-two-u-s-startups\\\/129855\\\/\"},\"author\":{\"name\":\"Emil Abirascid\",\"@id\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/#\\\/schema\\\/person\\\/4e2760db2cb7ca47d635ea3d8d8486dd\"},\"headline\":\"Angelini Ventures invests eight million euros in two U.S. startups\",\"datePublished\":\"2024-01-31T07:56:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/angelini-ventures-invests-eight-million-euros-in-two-u-s-startups\\\/129855\\\/\"},\"wordCount\":598,\"commentCount\":0,\"image\":{\"@id\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/angelini-ventures-invests-eight-million-euros-in-two-u-s-startups\\\/129855\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.startupbusiness.it\\\/wp-content\\\/uploads\\\/2024\\\/05\\\/AngeliniVentures_Team.jpg\",\"keywords\":[\"Corporate\",\"healthcare\",\"investments\",\"startup\",\"venture capital\"],\"articleSection\":[\"Funding News\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/angelini-ventures-invests-eight-million-euros-in-two-u-s-startups\\\/129855\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/angelini-ventures-invests-eight-million-euros-in-two-u-s-startups\\\/129855\\\/\",\"url\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/angelini-ventures-invests-eight-million-euros-in-two-u-s-startups\\\/129855\\\/\",\"name\":\"Angelini Ventures invests eight million euros in two U.S. startups\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/angelini-ventures-invests-eight-million-euros-in-two-u-s-startups\\\/129855\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/angelini-ventures-invests-eight-million-euros-in-two-u-s-startups\\\/129855\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.startupbusiness.it\\\/wp-content\\\/uploads\\\/2024\\\/05\\\/AngeliniVentures_Team.jpg\",\"datePublished\":\"2024-01-31T07:56:14+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/#\\\/schema\\\/person\\\/4e2760db2cb7ca47d635ea3d8d8486dd\"},\"description\":\"Noctrix Health and COUR Pharmaceuticals Develop Wearable Therapeutics and Nanotechnology to Fight Diabetes and Celiac Disease\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/angelini-ventures-invests-eight-million-euros-in-two-u-s-startups\\\/129855\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/angelini-ventures-invests-eight-million-euros-in-two-u-s-startups\\\/129855\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.startupbusiness.it\\\/wp-content\\\/uploads\\\/2024\\\/05\\\/AngeliniVentures_Team.jpg\",\"contentUrl\":\"https:\\\/\\\/www.startupbusiness.it\\\/wp-content\\\/uploads\\\/2024\\\/05\\\/AngeliniVentures_Team.jpg\",\"width\":1280,\"height\":853,\"caption\":\"Il team di Angelini Ventures\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/\",\"name\":\"Startupbusiness.it\",\"description\":\"May the Force be with you!\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/#\\\/schema\\\/person\\\/4e2760db2cb7ca47d635ea3d8d8486dd\",\"name\":\"Emil Abirascid\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/84e46190ac811c9c62650621ceca8f65c1e967d6b06e6352fe183145dba0d7e9?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/84e46190ac811c9c62650621ceca8f65c1e967d6b06e6352fe183145dba0d7e9?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/84e46190ac811c9c62650621ceca8f65c1e967d6b06e6352fe183145dba0d7e9?s=96&d=mm&r=g\",\"caption\":\"Emil Abirascid\"},\"description\":\"Emil Abirascid (\u30a8\u30df\u30fc\u30eb\u30fb\u30a2\u30d3\u30e9\u30b7\u30c3\u30c9), giornalista, fondatore e direttore di Startupbusiness, il primo magazine sull\u2019ecosistema startup e innovazione italiano. Co-fondatore di Designtech, l\u2019hub di innovazione che avvicina il mondo del design con quello della tecnologia. Advisor di Austrian Business Agency, Emil Banca, Fondazione Symbola, Fondazione Quadrans. Partecipa regolarmente a incontri, convegni, conferenze dedicate all\u2019ecosistema dell\u2019innovazione. E\u2019 stato co-organizzatore degli Italian Innovation Day and Series che si sono svolti dal dal 2016 al 2020 nelle citt\u00e0 di Tokyo in Giappone, Melbourne, Adelaide, Perth, Canberra in Australia e Singapore e co-organizzatore dell\u2019Italy India Innovation Day di AIICP 2021 e 2022. Ha curato il volume \u2018L\u2019innovazione che non ti aspetti. Contesti e visioni per l\u2019impresa\u2019 , l\u2019edizione italiana di \u2018La startup digitale, guida pratica step by step\u2019 e ha scritto la prefazione all\u2019edizione italiana de \u2018La quarta era\u2019 di Byron Reese, ed \u00e8 co-autore di \u2018Cosa e Dove: strategie digitali di ricerca del lavoro\u2019, tutti editi da FrancoAngeli. In passato \u00e8 stato curatore di StartupDigest Italy, coordinatore scientifico del Forum per la Ricerca della Provincia Autonoma di Trento, board member di TechChill Milano advisor di di ScaleIT , ha collaborato con Il Sole 24 Ore \u00e8 stato direttore di Innov\u2019azione, bimestrale edito da Apsti, ha collaborato con Corriere Innovazione ed \u00e8 stato presidente del comitato di selezione del Premio Marzotto e advisor di Cetif-Universit\u00e0 Cattolica Milano.\",\"sameAs\":[\"https:\\\/\\\/www.abirascid.com\\\/\",\"https:\\\/\\\/www.linkedin.com\\\/in\\\/emilabirascid\",\"https:\\\/\\\/x.com\\\/emilabirascid\"],\"url\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/author\\\/emil-abirascid\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Angelini Ventures invests eight million euros in two U.S. startups","description":"Noctrix Health and COUR Pharmaceuticals Develop Wearable Therapeutics and Nanotechnology to Fight Diabetes and Celiac Disease","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.startupbusiness.it\/en\/angelini-ventures-invests-eight-million-euros-in-two-u-s-startups\/129855\/","og_locale":"en_US","og_type":"article","og_title":"Angelini Ventures invests eight million euros in two U.S. startups","og_description":"Noctrix Health and COUR Pharmaceuticals Develop Wearable Therapeutics and Nanotechnology to Fight Diabetes and Celiac Disease","og_url":"https:\/\/www.startupbusiness.it\/en\/angelini-ventures-invests-eight-million-euros-in-two-u-s-startups\/129855\/","og_site_name":"Startupbusiness.it","article_published_time":"2024-01-31T07:56:14+00:00","og_image":[{"width":1280,"height":853,"url":"https:\/\/www.startupbusiness.it\/wp-content\/uploads\/2024\/05\/AngeliniVentures_Team.jpg","type":"image\/jpeg"}],"author":"Emil Abirascid","twitter_card":"summary_large_image","twitter_creator":"@emilabirascid","twitter_misc":{"Written by":"Emil Abirascid","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.startupbusiness.it\/en\/angelini-ventures-invests-eight-million-euros-in-two-u-s-startups\/129855\/#article","isPartOf":{"@id":"https:\/\/www.startupbusiness.it\/en\/angelini-ventures-invests-eight-million-euros-in-two-u-s-startups\/129855\/"},"author":{"name":"Emil Abirascid","@id":"https:\/\/www.startupbusiness.it\/en\/#\/schema\/person\/4e2760db2cb7ca47d635ea3d8d8486dd"},"headline":"Angelini Ventures invests eight million euros in two U.S. startups","datePublished":"2024-01-31T07:56:14+00:00","mainEntityOfPage":{"@id":"https:\/\/www.startupbusiness.it\/en\/angelini-ventures-invests-eight-million-euros-in-two-u-s-startups\/129855\/"},"wordCount":598,"commentCount":0,"image":{"@id":"https:\/\/www.startupbusiness.it\/en\/angelini-ventures-invests-eight-million-euros-in-two-u-s-startups\/129855\/#primaryimage"},"thumbnailUrl":"https:\/\/www.startupbusiness.it\/wp-content\/uploads\/2024\/05\/AngeliniVentures_Team.jpg","keywords":["Corporate","healthcare","investments","startup","venture capital"],"articleSection":["Funding News"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.startupbusiness.it\/en\/angelini-ventures-invests-eight-million-euros-in-two-u-s-startups\/129855\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.startupbusiness.it\/en\/angelini-ventures-invests-eight-million-euros-in-two-u-s-startups\/129855\/","url":"https:\/\/www.startupbusiness.it\/en\/angelini-ventures-invests-eight-million-euros-in-two-u-s-startups\/129855\/","name":"Angelini Ventures invests eight million euros in two U.S. startups","isPartOf":{"@id":"https:\/\/www.startupbusiness.it\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.startupbusiness.it\/en\/angelini-ventures-invests-eight-million-euros-in-two-u-s-startups\/129855\/#primaryimage"},"image":{"@id":"https:\/\/www.startupbusiness.it\/en\/angelini-ventures-invests-eight-million-euros-in-two-u-s-startups\/129855\/#primaryimage"},"thumbnailUrl":"https:\/\/www.startupbusiness.it\/wp-content\/uploads\/2024\/05\/AngeliniVentures_Team.jpg","datePublished":"2024-01-31T07:56:14+00:00","author":{"@id":"https:\/\/www.startupbusiness.it\/en\/#\/schema\/person\/4e2760db2cb7ca47d635ea3d8d8486dd"},"description":"Noctrix Health and COUR Pharmaceuticals Develop Wearable Therapeutics and Nanotechnology to Fight Diabetes and Celiac Disease","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.startupbusiness.it\/en\/angelini-ventures-invests-eight-million-euros-in-two-u-s-startups\/129855\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.startupbusiness.it\/en\/angelini-ventures-invests-eight-million-euros-in-two-u-s-startups\/129855\/#primaryimage","url":"https:\/\/www.startupbusiness.it\/wp-content\/uploads\/2024\/05\/AngeliniVentures_Team.jpg","contentUrl":"https:\/\/www.startupbusiness.it\/wp-content\/uploads\/2024\/05\/AngeliniVentures_Team.jpg","width":1280,"height":853,"caption":"Il team di Angelini Ventures"},{"@type":"WebSite","@id":"https:\/\/www.startupbusiness.it\/en\/#website","url":"https:\/\/www.startupbusiness.it\/en\/","name":"Startupbusiness.it","description":"May the Force be with you!","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.startupbusiness.it\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.startupbusiness.it\/en\/#\/schema\/person\/4e2760db2cb7ca47d635ea3d8d8486dd","name":"Emil Abirascid","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/84e46190ac811c9c62650621ceca8f65c1e967d6b06e6352fe183145dba0d7e9?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/84e46190ac811c9c62650621ceca8f65c1e967d6b06e6352fe183145dba0d7e9?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/84e46190ac811c9c62650621ceca8f65c1e967d6b06e6352fe183145dba0d7e9?s=96&d=mm&r=g","caption":"Emil Abirascid"},"description":"Emil Abirascid (\u30a8\u30df\u30fc\u30eb\u30fb\u30a2\u30d3\u30e9\u30b7\u30c3\u30c9), giornalista, fondatore e direttore di Startupbusiness, il primo magazine sull\u2019ecosistema startup e innovazione italiano. Co-fondatore di Designtech, l\u2019hub di innovazione che avvicina il mondo del design con quello della tecnologia. Advisor di Austrian Business Agency, Emil Banca, Fondazione Symbola, Fondazione Quadrans. Partecipa regolarmente a incontri, convegni, conferenze dedicate all\u2019ecosistema dell\u2019innovazione. E\u2019 stato co-organizzatore degli Italian Innovation Day and Series che si sono svolti dal dal 2016 al 2020 nelle citt\u00e0 di Tokyo in Giappone, Melbourne, Adelaide, Perth, Canberra in Australia e Singapore e co-organizzatore dell\u2019Italy India Innovation Day di AIICP 2021 e 2022. Ha curato il volume \u2018L\u2019innovazione che non ti aspetti. Contesti e visioni per l\u2019impresa\u2019 , l\u2019edizione italiana di \u2018La startup digitale, guida pratica step by step\u2019 e ha scritto la prefazione all\u2019edizione italiana de \u2018La quarta era\u2019 di Byron Reese, ed \u00e8 co-autore di \u2018Cosa e Dove: strategie digitali di ricerca del lavoro\u2019, tutti editi da FrancoAngeli. In passato \u00e8 stato curatore di StartupDigest Italy, coordinatore scientifico del Forum per la Ricerca della Provincia Autonoma di Trento, board member di TechChill Milano advisor di di ScaleIT , ha collaborato con Il Sole 24 Ore \u00e8 stato direttore di Innov\u2019azione, bimestrale edito da Apsti, ha collaborato con Corriere Innovazione ed \u00e8 stato presidente del comitato di selezione del Premio Marzotto e advisor di Cetif-Universit\u00e0 Cattolica Milano.","sameAs":["https:\/\/www.abirascid.com\/","https:\/\/www.linkedin.com\/in\/emilabirascid","https:\/\/x.com\/emilabirascid"],"url":"https:\/\/www.startupbusiness.it\/en\/author\/emil-abirascid\/"}]}},"author_name":"Emil Abirascid","categories_names":["Funding News"],"_links":{"self":[{"href":"https:\/\/www.startupbusiness.it\/en\/wp-json\/wp\/v2\/posts\/129855","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.startupbusiness.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.startupbusiness.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.startupbusiness.it\/en\/wp-json\/wp\/v2\/users\/125"}],"replies":[{"embeddable":true,"href":"https:\/\/www.startupbusiness.it\/en\/wp-json\/wp\/v2\/comments?post=129855"}],"version-history":[{"count":0,"href":"https:\/\/www.startupbusiness.it\/en\/wp-json\/wp\/v2\/posts\/129855\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.startupbusiness.it\/en\/wp-json\/wp\/v2\/media\/137025"}],"wp:attachment":[{"href":"https:\/\/www.startupbusiness.it\/en\/wp-json\/wp\/v2\/media?parent=129855"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.startupbusiness.it\/en\/wp-json\/wp\/v2\/categories?post=129855"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.startupbusiness.it\/en\/wp-json\/wp\/v2\/tags?post=129855"},{"taxonomy":"companies","embeddable":true,"href":"https:\/\/www.startupbusiness.it\/en\/wp-json\/wp\/v2\/companies?post=129855"},{"taxonomy":"journalist","embeddable":true,"href":"https:\/\/www.startupbusiness.it\/en\/wp-json\/wp\/v2\/journalist?post=129855"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}